Osteosarcoma and other bone cancers

Current Opinion in Oncology

Volumn 10, Issue 4, 1998, Pages 326-333

  Himelstein, Bruce P ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; IFOSFAMIDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; TUMOR VACCINE;

ARTICLE; BONE CANCER; CARTILAGE TUMOR; CHONDROSARCOMA; CHROMOSOME 3Q; ENDOPROSTHESIS; HEREDITARY MULTIPLE EXOSTOSIS; OSTEOSARCOMA; PRIORITY JOURNAL; SPINE TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0031878385     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199807000-00009     Document Type: Article

References (33)

1. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VHC, et al.: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997, 350:911-917. The EOI study compared treatment with 18 weeks of DOX/CDP with a 44-week multiagent regimen based on the Memorial Sloan-Kettering T10 protocol. Despite concerns about lack of dose intensity achieved with the longer regimen, comparable histologic responses and overall survival were seen with short intensive therapy.
2. Blum RH: Simplified vs complex adjuvant chemotherapy schedule for osteosarcoma. Lancet 1997, 350:900-901.
3. Meyers P, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al.: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10:5-15.
4. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al.: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997, 15:76-84.
5. Delepine N, Delepine G, Bacci G, Rosen G, Desbois J-C: Author reply [letter]. Cancer 1997, 80:517-518. In this revised meta-analysis of MTX dose intensity for the treatment of osteosarcoma, the authors excluded studies in which postoperative chemotherapy was modified based on histologic response. The results still clearly demonstrate a significant correlation between MTX dose intensity and survival.
6. Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, et al.: Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Cancer 1997, 79:245-254. This small study of patients with metastatic osteosarcoma suggests that achievement of complete remission using neoadjuvant therapy (MTX, CDP, DOX, and IFOS) followed by simultaneous excision of both the primary tumor and pulmonary metastases results in survival rates comparable to the rates of patients without metastases. Further, there was a significant rate of false-positive diagnostic chest CTs.
7. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al.: Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998, 16:658-663.
8. Gentet J-C, Brunat-Mentigny M, Demaille MC, Pein F, Avet-Loiseau H, Berger C, et al.: Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997, 33:232-237.
9. 2 given by either continuous infusion or by bolus) in patients with refractory bone sarcomas.
10. Cefalo G, Ferrari A, Tesoro-Tess JD, Gianni MC, Fossati-Bellani F, Lombardi F, Massimino M: Treatment of childhood post-irradiation sarcoma of bone in cancer survivors. Med Pediatr Oncol 1997, 29:568-572.
11. Delepine N, Delepine G, Bacci G, Rosen G, Desbois J-C: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature. Cancer 1996, 78:2127-2135.
12. Bielack SS, Beron G, Winkler K: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature. Cancer 1997, 80:516-518.
13. Smith MA, Ungerleider RS, Horowitz ME, Simon R: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991, 83:1460-1470.
14. Kruzelock RP, Murphy EC, Strong LC, Naylor SL, Hansen MF: Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 1997, 57:106-109. Loss of heterozygosity has been identified in a band on chromosome 3q in over two-thirds of patients with osteosarcoma, suggesting the presence of a novel tumor suppressor gene in this region. The LOH frequency approaches that for p53 and RB1, two gene products previously shown to be important in osteosarcoma development.
15. Horstmann MA, Posl M, Scholz RB, Anderegg B, Simon P, Baumgaert K, et al.: Frequent reduction or loss of DCC gene expression in human osteosarcoma. Br J Cancer 1997, 75:1309-1317.
16. Fazeli A, Dickinson S, Hermiston M, Tighe R, Steen R, Small C, et al.: Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 1997, 386:796-804.
17. Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, Pappo AS, et al.: Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997, 80:960-965.
18. Crnalic S, Hakansson I, Boquist L, Lofvenberg R, Brostrom L-A: A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin Exp Metastasis 1997, 15:164-172.
19. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS: Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997, 79:1409-1421.
20. Hayakawa M, Kawaguchi S, Ishii S, Murakami M, Uede T: B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Int J Cancer 1997, 71:1091-1102. Using a model of osteosarcoma spontaneous metastasis following orthotopic implantation in the tibia of mice, the authors have demonstrated that vaccination with lethally irradiated osteosarcoma cells expressing the T-cell costimulatory B7-1 molecule significantly decreased metastatic frequency and increased survival. These effects were synergistic with the effects of intraperitoneal MTX.
21. Larramendy ML, Tarkkanen M, Valle J, Kivioja AH, Ervasti H, Karaharju E, Salmivalli T, Elomaa I, Knuutila S: Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. Am J Pathol 1997, 150:685-691.
22. Swarts SJ, Neff JR, Nelson M, Johansson S, Bridge JA: Chromosomal abnormalities in low grade chondrosarcoma and a review of the literature. Cancer Genet Cytogenet 1997, 98:126-130.
23. Hecht JT, Hogue D, Wang Y, Blanton SH, Wagner M, Strong LC, et al.: Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies. Am J Hum Genet 1997, 60:80-86.
24. Rosier RN, O'Keefe RJ, Teot LA, Fox EJ, Nester TA, Puzas JE, et al.: P-glycoprotein expression in cartilaginous tumors. J Surg Oncol 1997, 65:95-105.
25. Verkerke GJ, Schraffordt Koops H, Veth RP, van Horn JR, Postma L, Grootenboer HJ: First clinical experience with a noninvasively extendable endoprosthesis: a limb-saving procedure in children suffering from a malignant bone tumor. Artif Organs 1997, 21:413-417. In this paper, the authors describe the first clinical application of an endoprosthesis that can be extended via an externally applied electromagnet. Despite manufacturing problems, this device holds promise for managing the problem of leg length discrepancy in children undergoing surgical excision of long bone tumors.
26. Tomita K, Kawahara N. Baba H, Tsuchiya H, Fujita T, Toribatake Y: Total en bloc spondylectomy. Spine 1997, 22:324-333.
27. Grimer RJ, Carter SR, Pynsent PB: The cost-effectiveness of limb salvage for bone tumours. J Bone Joint Surg Br 1997, 79-B:558-561. A cost analysis is presented that suggests that endoprosthetic reconstruction is more cost effective than amputation and external prostheses for femoral tumors. These data combined with previously published quality of life studies support the trend away from amputation for lower extremity bone tumors.
28. Panicek DM, Gatsonis C, Rosenthal DI, Seeger LL, Huvos AG, Moore SG, et al.: CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology 1997, 202:237-246.
29. Gronemeyer SA, Kauffman WM, Rocha MS, Steen RG, Fletcher BD: Fat-saturated contrast-enhanced T1-weighted MRI in evaluation of osteosarcoma and Ewing sarcoma. J Magn Reson Imaging 1997, 7:585-589.
30. Iwasawa T, Tanaka Y, Aida N, Okuzumi S, Nishihira H, Nishimura G: Microscopic intraosseous extension of osteosarcoma: assessment on dynamic contrast-enhanced MRI. Skeletal Radiol 1997, 26:214-221.
31. 201TI imaging may have an important role in predicting histologic response to treatment.
32. 99mTc-MIBI imaging suggests that the latter may have advantages in evaluating osteosarcoma response to therapy. Both radionuclide angiography and scintigraphy can be performed with the latter agent, which may allow a more accurate assessment of response to therapy.
33. Soderlund V, Larsson SA, Bauer HCF, Brosjo O, Larsson O, Jacobsson H: Use of 99mTc-MIBI scintigraphy in the evaluation of the response of osteosarcoma to chemotherapy. Eur J Nucl Med 1997, 24:511-515.